A Phase 3 interventional study of rabeprazole and rabeprazole in Gastroesophageal Reflux Disease (GERD), sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed. Open to participants aged 1 Year to 11 Years. Per ClinicalTrials.gov, last updated 2013-01-24.
Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.
Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one is the 18th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2009, is one of 16 in phase 3, and was the 26th registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →
Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 1 Year to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 5 · Phase 3 17 · Phase 4 8
First in 2001; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 127 is above the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 100 across the 39 interventional studies. Of the 38 that completed or were terminated, 15 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Pharmaceutical Research & Development, L.L.C., one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.
27 studies in Gastroesophageal Reflux by Johnson & Johnson: none open now, 1 under way, none of them phase 3. Of 26 finished, 9 (35%) have results posted.
Among the 27 studies in Gastroesophageal Reflux by Johnson & Johnson, this one is the 7th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2009, is one of 4 in phase 3, and was the 12th registered.
Johnson & Johnson’s Gastroesophageal Reflux studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 27 in Gastroesophageal Reflux:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to access the effectiveness and safety of oral rabeprazole in the treatment of acid-related disorders in pediatric patients, focusing specifically on the manifestation of GERD (symptomatic and erosive types).
This is a randomized, double-blind study that consists of two parts. In Part 1, the study will consist of 3 phases: a 14-day screening phase, a double-blind treatment phase of 12 weeks comparing two doses of study drug (0.5 mg/kg or 1.0 mg/kg groups based on patient's body weight), and an end-of-study or early withdrawal phase followed by Part 2, which consists a of double-blind treatment continuation for patients who have achieved healing during the short-term double-blind treatment phase. The double-blind maintenance treatment phase lasts for not more than 24 weeks and is concluded by an end-of-study/early withdrawal visit. During Part 1, patients will be screened and the diagnosis of erosive and non-erosive Gastroesophageal Reflux Disease (GERD) will be made based on clinical symptoms and confirmed by endoscopy/histology after a biopsy. Patients enrolled in the study will receive study drug once daily for 12 weeks. Each day, the parent/caregiver will record the presence and severity of pre-specified GERD symptoms. At Weeks 4 and 8, the investigator will evaluate the response to treatment by assessment of the GERD symptoms. At Week 12, the investigator will perform an endoscopy of the esophagus with a biopsy to confirm that histological healing has occurred. If a patient continues, additional study drug will be dispensed (at the same dose taken during the short-term double-blind treatment phase) and the patient will be scheduled to return every 8 weeks until study drug is discontinued at Week 24 (Part 2) of the double-blind maintenance treatment phase. At the final visit of the maintenance treatment phase Week 24 (Part 2), assessments including an endoscopy of the esophagus with a biopsy be performed for each patient. Assessments of effectiveness include endoscopic and histological grading of biopsy samples, GERD symptom and severity score (symptoms and severity rated daily by the parent/caregiver in an electronic diary), overall GERD symptom relief, Clinical Global Impression of Improvement (CGI-I) score, and the Global Treatment Satisfaction Score. Safety assessments will include the monitoring of concomitant therapies and adverse events throughout the study, clinical laboratory testing (including hematology, clinical chemistry, urinalysis), vital signs, and physical examination including height, weight, and Tanner staging. Oral rabeprazole 2.5 capsules or 5 mg capsules, given once daily at a dose of 0.5 mg/kg or 1.0 mg/kg; short-term treatment phase is 12 weeks; long-term maintenance treatment phase is 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
rabeprazole 0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
Drug: rabeprazole
rabeprazole 1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
Drug: rabeprazole
0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
The Percentage of Patients With Healing by Week 12 (Short-term Double-blind Treatment Phase)
Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa.
Time frame: 12 weeks
The Percentage of Patients With Healing by Week 36 (Double-blind Maintenance Treatment Phase)
Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa.
Time frame: 36 weeks
The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Short-term Double-blind Treatment Phase)
The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement.
Time frame: Baseline, Week 12
The Change From Baseline in the Total GERD Symptom and Severity Score (Short-term Double-blind Treatment Phase)
The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement.
Time frame: Baseline, Week 12
The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Double-blind Maintenance Treatment Phase)
The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement.
Time frame: Baseline, Week 36
The Change From Baseline in the Total GERD Symptom and Severity Score (Double-blind Maintenance Treatment Phase)
The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement.
Time frame: Baseline, Week 36
| Milestone | Rabeprazole 0.5 mg/kg | Rabeprazole 1.0 mg/kg |
|---|---|---|
| Started | 65 | 62 |
| Completed | 55 | 53 |
| Not completed | 10 | 9 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 6 | 2 |
| Withdrew: Other | 0 | 2 |
| Milestone | Rabeprazole 0.5 mg/kg | Rabeprazole 1.0 mg/kg |
|---|---|---|
| Started | 33 | 31 |
| Completed | 26 | 24 |
| Not completed | 7 | 7 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Non-compliance with study drug | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Other | 5 | 2 |
Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa.
| Percentage of participants | Rabeprazole Sodium 0.5 mg/kg | Rabeprazole Sodium 1.0 mg/kg |
|---|---|---|
| The Percentage of Patients With Healing by Week 12 (Short-term Double-blind Treatment Phase) | 78 (67 to 89) | 83 (73 to 93) |
Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa.
| Percentage of patients | Rabeprazole Sodium 0.5 mg/kg | Rabeprazole Sodium 1.0 mg/kg |
|---|---|---|
| The Percentage of Patients With Healing by Week 36 (Double-blind Maintenance Treatment Phase) | 92 (82 to 100) | 88 (76 to 100) |
The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement.
| Scores on a scale | Rabeprazole Sodium 0.5 mg/kg | Rabeprazole Sodium 1.0 mg/kg |
|---|---|---|
| The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Short-term Double-blind Treatment Phase) | -1.3 ± 0.85 | -1.0 ± 0.81 |
The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement.
| Scores on a scale | Rabeprazole Sodium 0.5 mg/kg | Rabeprazole Sodium 1.0 mg/kg |
|---|---|---|
| The Change From Baseline in the Total GERD Symptom and Severity Score (Short-term Double-blind Treatment Phase) | -11.5 ± 11.70 | -8.5 ± 9.75 |
The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement.
| Scores on a scale | Rabeprazole Sodium 0.5 mg/kg | Rabeprazole Sodium 1.0 mg/kg |
|---|---|---|
| The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Double-blind Maintenance Treatment Phase) | 0.2 ± 0.49 | 0.2 ± 0.54 |
The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement.
| Scores on a scale | Rabeprazole Sodium 0.5 mg/kg | Rabeprazole Sodium 1.0 mg/kg |
|---|---|---|
| The Change From Baseline in the Total GERD Symptom and Severity Score (Double-blind Maintenance Treatment Phase) | -2.9 ± 4.82 | -1.4 ± 9.59 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rabeprazole 0.5 mg/kg (Short-term Double-blinde Phase) | — | 5/65 (7.7%) | 47/65 (72.3%) |
| Rabeprazole 1.0 mg/kg (Short-term Double-blinde Phase) | — | 1/62 (1.6%) | 47/62 (75.8%) |
| Rabeprazole 0.5 mg/kg (Double-blind Maintenance Phase) | — | 2/33 (6.1%) | 18/33 (54.5%) |
| Rabeprazole 1.0 mg/kg (Double-blind Maintenance Phase | — | 3/31 (9.7%) | 21/31 (67.7%) |
| Event | Rabeprazole 0.5 mg/kg (Short-term Double-blinde Phase) | Rabeprazole 1.0 mg/kg (Short-term Double-blinde Phase) | Rabeprazole 0.5 mg/kg (Double-blind Maintenance Phase) | Rabeprazole 1.0 mg/kg (Double-blind Maintenance Phase |
|---|---|---|---|---|
| BronchopneumoniaInfections and infestations | 1/65 | 0/62 | 0/33 | 1/31 |
| LymphadenitisBlood and lymphatic system disorders | 0/65 | 0/62 | 0/33 | 1/31 |
| Conversion DisorderPsychiatric disorders | 0/65 | 0/62 | 0/33 | 1/31 |
| Head InjuryInjury, poisoning and procedural complications | 0/65 | 0/62 | 1/33 | 0/31 |
| Partial Seizures with Secondary GeneralisationNervous system disorders | 0/65 | 0/62 | 1/33 | 0/31 |
| GastroenteritisInfections and infestations | 0/65 | 1/62 | 0/33 | 0/31 |
| BronchitisInfections and infestations | 1/65 | 0/62 | 0/33 | 0/31 |
| Gastrointestinal InfectionInfections and infestations | 1/65 | 0/62 | 0/33 | 0/31 |
| PneumoniaInfections and infestations | 1/65 | 0/62 | 0/33 | 0/31 |
| Humerus FractureInjury, poisoning and procedural complications | 1/65 | 0/62 | 0/33 | 0/31 |
| Event | Rabeprazole 0.5 mg/kg (Short-term Double-blinde Phase) | Rabeprazole 1.0 mg/kg (Short-term Double-blinde Phase) | Rabeprazole 0.5 mg/kg (Double-blind Maintenance Phase) | Rabeprazole 1.0 mg/kg (Double-blind Maintenance Phase |
|---|---|---|---|---|
| VomitingGastrointestinal disorders | 8/65 | 10/62 | 4/33 | 3/31 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/65 | 9/62 | 2/33 | 0/31 |
| Abdominal PainGastrointestinal disorders | 7/65 | 8/62 | 3/33 | 2/31 |
| Upper Respiratory Tract InfectionInfections and infestations | 6/65 | 4/62 | 4/33 | 4/31 |
| PyrexiaGeneral disorders | 8/65 | 5/62 | 0/33 | 3/31 |
| DiarrhoeaGastrointestinal disorders | 7/65 | 7/62 | 1/33 | 3/31 |
| HeadacheNervous system disorders | 4/65 | 7/62 | 1/33 | 0/31 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 2/65 | 6/62 | 0/33 | 2/31 |
| DyspepsiaGastrointestinal disorders | 1/65 | 1/62 | 0/33 | 2/31 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 4/65 | 1/62 | 0/33 | 0/31 |
| Age, Categorical(Participants) | Rabeprazole 0.5 mg/kg | Rabeprazole 1.0 mg/kg | Total |
|---|---|---|---|
| <=18 years | 65 | 62 | 127 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age Continuous(years) | Rabeprazole 0.5 mg/kg | Rabeprazole 1.0 mg/kg | Total |
|---|---|---|---|
| Mean | 5.9 ± 3.49 | 5.4 ± 3.26 | 5.7 ± 3.37 |
| Sex: Female, Male(Participants) | Rabeprazole 0.5 mg/kg | Rabeprazole 1.0 mg/kg | Total |
|---|---|---|---|
| Female | 31 | 25 | 56 |
| Male | 34 | 37 | 71 |
| Baseline BMI(kg/cm2) | Rabeprazole 0.5 mg/kg | Rabeprazole 1.0 mg/kg | Total |
|---|---|---|---|
| Mean | 17.5 ± 4.08 | 16.8 ± 3.11 | 17.2 ± 3.64 |
No study locations are listed for this record.
The record gives a start of Jan 2009, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 1 year 9 months after primary completion. A results delay was requested in Jul 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rabeprazole
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. →